Cargando…

Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Most of the patients of PDAC present at later stages of disease and have a five-year survival rate of less than 10%. About 5–10% PDAC cases are hereditary in nature and have DNA damage repair (DDR) mutations such as BRCA 1 and 2. B...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Medhavi, Iyer, Renuka, Fountzilas, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966572/
https://www.ncbi.nlm.nih.gov/pubmed/31835379
http://dx.doi.org/10.3390/cancers11121980